Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco

Chaoui, Imane; Oudghiri, Amal; Mzibri, Mohammed El

doi:10.1016/j.jgar.2017.10.003

Cited by 16 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reports mentioned that most FQs-resistant MTB isolates had mutations in the QRDR of DNA gyrase, which is the case of the present study, as 67.5% of phenotypically OFX-resistant isolates were found to harbor mutations in gyrA or gyrB genes. Our results showed that Ala90Val was the most predominant substitution (52.2%; 12/23) in contrast to previous studies reporting the predominance of Asp94Gly (25%) 14 , Ala90Thr (50%) 13 and Asp94Ala (67.6%) substitutions 11 .…”

Section: Discussioncontrasting

confidence: 99%

“…The emergence of pre-extensively and extensively drug-resistant tuberculosis (Pre-XDR/XDR-TB) among MDR-TB isolates represents a serious hurdle for TB Mutations in DNA gyrase conferring resistance to quinolones have been extensively studied 7,8,13 . Several reports mentioned that most FQs-resistant MTB isolates had mutations in the QRDR of DNA gyrase, which is the case of the present study, as 67.5% of phenotypically OFX-resistant isolates were found to harbor mutations in gyrA or gyrB genes.…”

Section: Discussionmentioning

confidence: 99%

“…A first preliminary study on mutations within gyrA and gyrB genes on MTB isolates from a laboratory collection (2003)(2004)(2005)(2006)(2007) with a small panel of MDR-TB isolates from Morocco was conducted by Chaoui et al 13 . Later on, Oudghiri et al 11 screened for mutations in gyrA, gyrB, rrs, tlyA genes and the eis promoter region, and their frequencies within MDR-MTB clinical isolates associated with resistance to SLDs, in a large panel of clinical isolates from TB patients recruited from 2009 to 2012 in Casablanca, the highest TB incidence region in Morocco.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Molecular characterization of mutations associated with resistance to second line drugs in Mycobacterium tuberculosis patients from Casablanca, Morocco

Momen

Aainouss

Lamaammal

et al. 2021

Rev. Inst. Med. trop. S. Paulo

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular characterization of mutations associated with resistance to second line drugs in Mycobacterium tuberculosis patients from Casablanca, Morocco

Momen

Aainouss

Lamaammal

et al. 2021

Rev. Inst. Med. trop. S. Paulo

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our present study, mutations at gyrA codon 89, 90, 91, and 94 were observed in 75.3% of resistant isolates. The frequency of mutations conferring FQ r is similar to Shanghai (76.0%), although it is lower than those in Russia (83.0%), India (81.0%) and Thailand (92.3%), and higher than those in Morocco (30.0%) and New York (67.0%) (Sullivan et al, 1895; Mokrousov et al, 2008; Zhu et al, 2012; Disratthakit et al, 2016; Singhal et al, 2016; Chaoui et al, 2018), indicating that mutations in gyrA tend to differ by geographic region. In line with previous studies (Singhal et al, 2016; Pang et al, 2017; Chawla et al, 2018), substitutions at codon 94 were the most frequent mutation among FQ r isolates.…”

Section: Discussionmentioning

confidence: 86%

Mutation and Transmission Profiles of Second-Line Drug Resistance in Clinical Isolates of Drug-Resistant Mycobacterium tuberculosis From Hebei Province, China

Gao

Zhang

et al. 2019

Front. Microbiol.

View full text Add to dashboard Cite

The emergence of drug-resistant tuberculosis (TB) is involved in ineffective treatment of TB, especially multidrug resistant/extensively resistant TB (MDR/XDR-TB), leading to acquired resistance and transmission of drug-resistant strains. Second-line drugs (SLD), including both fluoroquinolones and injectable drugs, were commonly proved to be the effective drugs for treatment of drug-resistant TB. The purpose of this study was to investigate the prevalence of SLD-resistant strains and its specific mutations in drug-resistant Mycobacterium tuberculosis clinical isolates, and to acknowledge the transmission pattern of SLD resistance strains in Hebei. The genes gyrA , gyrB , rrs , eis promoter and tlyA of 257 drug-resistant clinical isolates were sequenced to identify mutations that could be responsible for resistance against fluoroquinolones and second-line injectable drugs. Each isolate was genotyped by Spoligotyping and 15-loci MIRU-VNTR. Our results indicated that 48.2% isolates were resistant to at least one of five SLD. Of them, 37.7% isolates were resistant to fluoroquinolones and 24.5% isolates were resistant to second-line injectable drugs. Mutations in genes gyrA , gyrB , rrs , eis promoter and tlyA were detected in 73 (75.3%), 7 (7.2%), 24 (38.1%), 5 (7.9%), and 3 (4.8%) isolates, respectively. The most prevalent mutations were the D94G (23.7%) in gyrA gene and the A1401G (33.3%) in rrs gene. A combination of gyrA , rrs and eis promoter can act as a valuable predicator for predicting XDR phenotype. These results highlight the development of rapid diagnosis are the effective manners for the control of SLD-TB or XDR-TB.

show abstract

“…DNA gyrase is encoded by the gyrA and gyrB genes. 7 , 8 In contrast, aminoglycosides inhibit protein synthesis by binding to the ribosome near the A site. The primary mechanism of acquires resistance to aminoglycosides in mycobacteria is based on modification of the 30S subunit of the ribosome as the drug target.…”

Section: Introductionmentioning

confidence: 99%

Single-nucleotide polymorphisms related to fluoroquinolone and aminoglycoside resistance in <em>Mycobacterium avium</em> isolates

Hui¹,

Wan²,

Wei³

2018

IDR

View full text Add to dashboard Cite

ObjectiveThe relationships between fluoroquinolone and aminoglycoside resistance and single-nucleotide polymorphisms (SNPs) in gyrA, gyrB, and rpsL genes were investigated in 95 clinical isolates of Mycobacterium avium from China.MethodsFluoroquinolone and aminoglycoside resistance were determined by the broth microdilution method. GyrA, gyrB, and rpsL were sequenced, SNPs were identified, and the corresponding amino acid mutations were recorded.ResultsThe M. avium isolates displayed high levels of ofloxacin (93.68%), ciprofloxacin (92.63%), and streptomycin (65.26%) resistance. Moxifloxacin (18.95%) and amikacin (2.11%) were highly active against the strains. Fluoroquinolone resistance involving gyrA and gyrB gene mutations was identified. For gyrA, the most frequent SNPs were T→C (71/95, 74.74%), followed by A→G (64/95, 67.37%) and T→C (62/95, 65.26%). The amino acid mutations occurred mainly at Gly2444Asp (GGT→GAT) (20/95, 21.05%), Ala2445Ser (GCC→TCC) (20/95, 21.05%), Ala2447Val (GCC→GTC) (20/95, 21.05%), Val2449Ile (GTC→ATC) (20/95, 21.05%), and Glu2450Gln (GAA→CAA) (20/95, 21.05%). Prominent SNPs in gyrB included A→C (69/95, 72.63%), C→T (51/95, 53.68%), and T→G (29/95, 30.53%), and their amino acid substitutions were Ile2160Val (ATT→GTT) (21/95, 22.11%), Ile2160Met (ATT→ATG) (20/95, 21.05%), and Ile2273Leu (ATC→CTC) (11/95, 11.58%). Among the strains with aminoglycoside resistance, SNPs in rpsL were identified mostly at position G→A (73/95, 76.84%). G→C (21/95, 22.11%) was commonly seen. The amino acid mutations primarily involved Ala1539985Thr (GCC→ACC) (19/95, 20.00%), His1539992Asp (CAC→GAC) (19/95, 20.00%), and Gln-1539983Glu (CAG→GAG) (18/95, 18.95%).ConclusionOur study provides valuable information that could be used for the future diagnosis and treatment of M. avium disease.

show abstract

Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco

Cited by 16 publications

References 16 publications

Molecular characterization of mutations associated with resistance to second line drugs in Mycobacterium tuberculosis patients from Casablanca, Morocco

Molecular characterization of mutations associated with resistance to second line drugs in Mycobacterium tuberculosis patients from Casablanca, Morocco

Mutation and Transmission Profiles of Second-Line Drug Resistance in Clinical Isolates of Drug-Resistant Mycobacterium tuberculosis From Hebei Province, China

Single-nucleotide polymorphisms related to fluoroquinolone and aminoglycoside resistance in <em>Mycobacterium avium</em> isolates

Contact Info

Product

Resources

About